Longitudinal Population-based Observational Study of COVID-19 in the UK Population (COVIDENCE UK)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04330599 |
Recruitment Status :
Active, not recruiting
First Posted : April 1, 2020
Last Update Posted : January 31, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
COVIDENCE UK is a population-based observational longitudinal study that has the following objectives:
- To determine risk factors for incident COVID-19 and for adverse outcomes of COVID-19 in the UK population
- To characterise the natural history of COVID-19 in the UK population
- To evaluate the impact of COVID-19 on the physical and mental health of the UK population
- To provide a resource from which to identify potential participants for future clinical trials, and to use data collected in COVIDENCE as comparison or control data for trial participants who have been randomised to receive one or more interventions.
Condition or disease |
---|
COVID-19 |
Study Type : | Observational |
Actual Enrollment : | 13000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Longitudinal Population-based Observational Study of COVID-19 in the UK Population |
Actual Study Start Date : | May 1, 2020 |
Estimated Primary Completion Date : | April 1, 2025 |
Estimated Study Completion Date : | April 1, 2025 |

- Incidence of confirmed COVID-19 [ Time Frame: 5 years ]
- Incidence of probable or suspected COVID-19 [ Time Frame: 5 years ]
- Incidence of COVID-19 requiring hospitalisation [ Time Frame: 5 years ]
- Incidence of COVID-19 requiring ventilatory support [ Time Frame: 5 years ]
- Incidence of fatal COVID-19 [ Time Frame: 5 years ]
- Symptom duration per COVID-19 episode [ Time Frame: 5 years ]
- Symptom severity per COVID-19 episode [ Time Frame: 5 years ]
- Incidence of seroconversion to SARS-CoV-2 [ Time Frame: 5 years ]
- Incidence of recurrent COVID-19 [ Time Frame: 5 years ]
- EQ-5D-3L health-related quality of life score [ Time Frame: 5 years ]
- Health care costs associated with incident COVID-19 [ Time Frame: 5 years ]
- Impact of the COVID-19 pandemic and the societal response on participants' financial status [ Time Frame: 5 years ]
- Incidence of COVID-19 on participant's physical health [ Time Frame: 5 years ]
- Impact of COVID-19 on participants' mental health [ Time Frame: 5 years ]
- Impact of COVID-19 on physical health of offspring born to participants during follow-up [ Time Frame: 5 years ]
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- UK resident
- Age ≥16 years
Exclusion Criteria: none

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04330599
United Kingdom | |
Queen Mary University of London | |
London, County (optional), United Kingdom, E1 2AB |
Responsible Party: | Queen Mary University of London |
ClinicalTrials.gov Identifier: | NCT04330599 |
Other Study ID Numbers: |
COVIDENCE UK |
First Posted: | April 1, 2020 Key Record Dates |
Last Update Posted: | January 31, 2022 |
Last Verified: | January 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |